-
The next time you need to purchase a laser, how would you like to pay $8,000 for a used one instead of $30,000 or $50,000-$100,000 to purchase a new one? Those were the options faced by one ophthalmologist who turned to the Internet when he needed a CO2 laser.
-
For the first time since 1996, the Centers for Disease Control and Prevention (CDC) will conduct the National Survey of Ambulatory Surgery (NSAS).
-
The most recent Sentinel Event Alert issued by the Joint Commission on the Accreditation of Healthcare Organizations addresses medication reconciliation and the importance of this process in reducing the risk of medication errors.
-
This year's annual scientific sessions of the American College of Cardiology (ACC; Bethesda, Maryland), held here in early March, included a newly launched meeting-within-a meeting focusing on interventional cardiology, a change that is indicative of the growing importance of device-based therapies in cardiovascular disease. Drug-eluting stents (DES) continue to play a key role in market expansion, and now dominate the field of percutaneous intervention (PCI) in the U.S. and, increasingly, in Europe.
-
Guidant (Indianapolis) and its Cardiac Rhythm Management (CRM) business do not have a process for comprehensive internal or external medical review of the clinical impact of product malfunction.
-
MicroMed Cardiovascular (Houston), which is focused on the development of miniaturized implantable ventricular assist technology, said it has initiated a multicenter evaluation of its newest design of the DeBakey VAD (ventricular assist device).
-
Angiotech Pharmaceuticals (Vancouver, British Columbia) reported expiration of the FTC's waiting period for its purchase of American Medical Systems Holdings (AMI; Lake Forest, Illinois), allowing it to proceed with the $785 million all-cash acquisition, subject to satisfying remaining conditions.
-
Angiography for female patients who have presented with symptoms of cardiac distress appear to be not effective in determining the possible extent of coronary artery disease that may actually exist, according to new research.
-
Andrew Reed, PhD, has joined CardioTech International (Wilmington, Massachusetts) as vice president of technology in charge of CardioPass coronary artery bypass development and biomaterials.
-
An anniversary, especially a 10-year one, would typically be a cause for a festive celebration. However, at this year's 31st annual International Stroke Conference, sponsored by the American Stroke Association (ASA; Dallas) and held here in February, the 10th anniversary of the FDA's 1996 approval of Genentech's (South San Francisco, California) clot-busting drug tissue plasminogen activator (tPA) was noted in muted style.
